[2] [3] The dose-dependent nature of these effects explains why gastrointestinal symptoms are most prominent during treatment initiation and dose escalation
Many people also report feeling more energized
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
GIPR activation produces: Additional glucose-dependent insulin secretion (synergistic with GLP-1R on -cells) Direct effects on adipocyte (fat cell) lipid metabolism, including enhanced lipid uptake and storage dynamics paradoxically, this appears to contribute to improved metabolic outcomes by improving adipose tissue function rather than simply increasing fat storage Bone metabolism regulation GIPR is expressed in osteoblasts and osteoclasts and influences bone turnover (research area) Central nervous system effects via hypothalamic GIPR that are distinct from but complementary to GLP-1R appetite circuits The synergy between GIPR and GLP-1R at the -cell level amplifies insulin secretion beyond what either receptor achieves alone
Conclusion There are peptide stacks that can bring clear, focused fertility assistance to the table as well
Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying
